{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-038101","form_type":"8-K","ticker":"SGMT","cik":"0001400118","company_name":"Sagimet Biosciences Inc.","filed_at":"2024-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.059234+00:00","generated_at":"2026-06-04T08:24:25.476949+00:00","sec_items":["2.02","5.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sagimet FY2023 net loss $27.9M; denifanstat Phase 2b hits endpoints; board adds Walbert, Hoelscher","bullets":["Net loss $27.9M for FY2023 vs $30.5M in 2022; revenue $2.0M from milestone payment.","Cash, equivalents and securities $94.9M at Dec 31, 2023; Jan 2024 offering added $104.7M net.","Denifanstat Phase 2b FASCINATE-2 met primary endpoints: MASH resolution 36% vs 13% (p=0.0022); fibrosis improvement 41% vs 18% (p=0.005).","Board expanded from 7 to 9 directors; Tim Walbert (ex-Horizon CEO) and Paul Hoelscher (ex-Horizon CFO) appointed eff. April 1, 2024.","Directors Richard Rodgers and Jinzi Wu will not stand for re-election at June 2024 annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-038101","json":"https://secwatch.observer/filing/0001104659-24-038101.json","markdown":"https://secwatch.observer/filing/0001104659-24-038101.md","text":"https://secwatch.observer/filing/0001104659-24-038101.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1400118/000110465924038101/0001104659-24-038101-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1400118/000110465924038101/tm249600d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T08:24:25.476949+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6e113c7d5408cd4979a91b2128422d22b26a3e4e","claim":"Sagimet Biosciences Inc. reported fourth quarter and year ended December 31, 2023 results: revenue $2.0 million.","evidence_excerpt":"offering, are expected to fund operations for at least the next 12 months based on management’s current operating plan. · Revenues for the year ended December 31, 2023 were $2.0 million compared to no revenues for fiscal 2022. The increase was due to a $2.0 million milestone payment that was recognized in July 2023. · Research and development (R&D) expense for","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1400118/000110465924038101/0001104659-24-038101-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and year ended December 31, 2023"},{"label":"Revenue","value":"$2.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"672f120e0a","claim":"Paul Hoelscher was appointed as Director at Sagimet Biosciences Inc..","evidence_excerpt":"the appointment of each of Tim Walbert and Paul Hoelscher to serve as directors of the Board, in each case effective as of April 1, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1400118/000110465924038101/0001104659-24-038101-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"b640a724f5","claim":"Tim Walbert was appointed as Director at Sagimet Biosciences Inc..","evidence_excerpt":"the appointment of each of Tim Walbert and Paul Hoelscher to serve as directors of the Board, in each case effective as of April 1, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1400118/000110465924038101/0001104659-24-038101-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}